Merus
-
Ticker
MRUS
-
Industry
Biotechnology More
-
Sector
Healthcare More
- 51-200 Employees
- Based in Utrecht, Netherlands
Merus is developing best-in-class therapeutics to treat and potentially cure cancer patients. Their most advanced development programs use the Biclonics® format. Biclonics® are capable of simultaneously attacking tumors in multiple ways. For example by activating the immune system to kill tumor cells and directly inhibiting tumor cell growth and survival pathways.
REPORT RATINGS
4.8 / 5.0 (106)
Merus reports have an aggregate usefulness score of 4.8 based on 106 reviews.
Merus
Most Recent Annual Report
MOST RECENT
2023 Annual Report and Form 10K
Older/Archived Annual Reports